Beyond the guidelines in the treatment of peripheral T-cell lymphoma

New drug development

Andy Chen, Ranjana H. Advani

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.

Original languageEnglish (US)
Pages (from-to)428-435
Number of pages8
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume6
Issue number4
StatePublished - Apr 2008
Externally publishedYes

Fingerprint

Peripheral T-Cell Lymphoma
Guidelines
Pharmaceutical Preparations
Therapeutics
International Cooperation
Antimetabolites
Histone Deacetylase Inhibitors
T-Cell Lymphoma
B-Cell Lymphoma
Sample Size
Immunotherapy
Lymphoma

Keywords

  • Antimetabolites
  • Histone deacetylase inhibitor
  • Immunotherapy
  • Peripheral T-cell lymphoma
  • Targeted therapy

ASJC Scopus subject areas

  • Oncology

Cite this

Beyond the guidelines in the treatment of peripheral T-cell lymphoma : New drug development. / Chen, Andy; Advani, Ranjana H.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 6, No. 4, 04.2008, p. 428-435.

Research output: Contribution to journalArticle

@article{da6c90fae14b49a5b4f30c147c94f1ca,
title = "Beyond the guidelines in the treatment of peripheral T-cell lymphoma: New drug development",
abstract = "Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.",
keywords = "Antimetabolites, Histone deacetylase inhibitor, Immunotherapy, Peripheral T-cell lymphoma, Targeted therapy",
author = "Andy Chen and Advani, {Ranjana H.}",
year = "2008",
month = "4",
language = "English (US)",
volume = "6",
pages = "428--435",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "4",

}

TY - JOUR

T1 - Beyond the guidelines in the treatment of peripheral T-cell lymphoma

T2 - New drug development

AU - Chen, Andy

AU - Advani, Ranjana H.

PY - 2008/4

Y1 - 2008/4

N2 - Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.

AB - Peripheral T-cell lymphomas (PTCLs) are a rare and diverse group of neoplasms with a poor prognosis. Management of these disorders has been largely extrapolated from the treatment of aggressive B-cell lymphomas; however, therapeutic responses to this approach are neither adequate nor durable for most patients with PTCL. Given the rarity of PTCL, much of the literature consists of studies with small sample size and anecdotal case reports. Therefore, no consensus exists on the best therapeutic strategy for either newly diagnosed or relapsed/refractory PTCL. This article reviews promising novel approaches in the treatment of PTCL and its subtypes. Investigation into the pathogenesis of PTCL has also identified new targets for treatment. These emerging therapies include new uses of existing agents and the development of novel agents specifically targeted against T-cell lymphoma. Results using antimetabolites, immunotherapies, and histone deacetylase inhibitors have been particularly encouraging. These novel therapies are being tested as single agents and in combination with conventional lymphoma regimens in the frontline and salvage settings. Because of the rarity and heterogeneity of PTCL, national and international cooperation is needed to conduct the clinical studies required for the development of more effective treatment paradigms. These efforts are ongoing and will hopefully guide new strategies to improve the historically poor outcome of PTCL.

KW - Antimetabolites

KW - Histone deacetylase inhibitor

KW - Immunotherapy

KW - Peripheral T-cell lymphoma

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=43149105157&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=43149105157&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 428

EP - 435

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 4

ER -